Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report

Thorac Cancer. 2020 Sep;11(9):2717-2722. doi: 10.1111/1759-7714.13569. Epub 2020 Jul 13.


A 53-year-old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first-line setting. After disease progression, he received targeted therapy because of subsequent detection of EGFR exon 19 del mutation. Following an increase in his adrenal metastases, a combination of immunotherapy and antiangiogenic therapy (sintilimab plus bevacizumab) was commenced. After one month, imaging showed that the adrenal metastases had shrunk and a progression-free survival (PFS) of 6.0 months was achieved. In this case, we showed that the PD1 inhibitor sintilimab plus bevacizumab was effective in a refactory advanced EGFR-mutant NSCLC with positive PD-L1 expression. KEY POINTS: Our case report provides clinical evidence of the durable response of a patient with advanced EGFR-mutant lung adenocarcinoma to a combination of immunotherapy and anti-angiogenic agent, sintilimab and bevacizumab, as subsequent-line therapy. Sintilimab and bevacizumab combination therapy was well-tolerated and effective, resulting in dramatic tumor reduction and improvement in clinical symptoms.

Keywords: EGFR-mutant; NSCLC; PD-1; resistance; sintilimab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / pharmacology
  • Bevacizumab / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Humans
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged


  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • sintilimab